Eton Pharmaceuticals Inc. (ETON) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
- Abbott plans to spin off its nutrition unit as a standalone public company
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
- Anthropic logged net loss of over $80 billion in first half of 2026
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 11, 2022 4:01 PM EDTTotal Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on rare disease strategyU.S. Food and Drug Administration (FDA) Approval of Zonisade (zonisamide oral suspension)
DEER PARK, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial... More



